Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US03843E1047
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00L9HP0Z0
AQST
Aquestive Therapeutics Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Drug Manufacturers - Specialty & Generic · THEMEFOLIO: $HLTH
NAME
Aquestive Therapeutics Inc
ISIN
US03843E1047
TICKER
AQST
MIC
XNAS
REUTERS
AQST.OQ
BLOOMBERG
AQST US
Tue, 10.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.03.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, March 10, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encou...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.03.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced an inducement grant for Matthew Greenhawt, MD, MBA, MSc,...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 08.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 06.03.2026       Aquestive Therapeutics
US03843E1047

SAN DIEGO, March 6, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 and January 8, 2026. Aquestive is a pharmaceutical company committed to advancing medicines to bring impr...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 06.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260306007771/en/ Faruqi & Faruqi is a leading natio...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 06.03.2026       Aquestive Therapeutics
US03843E1047

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 and January 8, 2026. Aquestive is a pharmaceutical company committed to advancing medicines to bring improvement to patients’ lives through innova...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.03.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.03.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today reported financial results for the fourth quarter and full year end...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 28.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 25.02.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.02.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended D...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 21.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.02.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that multiple poster presentations highlighting results fr...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.02.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Matthew Greenhawt, MD, MBA, MSc, as Chi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 13.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 07.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 06.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses in Aquestive Therapeutics to Contact Him Directly to Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.02.2026       Aquestive Therapeutics
US03843E1047

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (“Aquestive” or “the Company”) (NASDAQ: AQST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.02.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it received a Complete Response Letter (CRL) from the...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.02.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - February 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. ("Aquestive Therapeutics, Inc.") (NASDAQ: AQST) concerning potential violations of the federal securities laws.What Happened?On January 9, 2026, Aquestive announced it received a...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.02.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 31.01.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.01.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.01.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.01.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 26.01.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - January 26, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. ("Aquestive Therapeutics, Inc.") (NASDAQ: AQST) concerning potential violations of the federal securities laws.What Happened?On January 9, 2026, Aquestive announced it received a...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.01.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.01.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.01.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive Therapeutics, Inc.") concerning potential violations of the federal securities laws.What Happened?On January 9, 2026, Aquestive announced i...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 17.01.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.01.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 14.01.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. ("Aquestive Therapeutics, Inc.") (NASDAQ: AQST) concerning potential violations of the federal securities laws.What Happened?On January 9, 2026, Aquestive announced it received a...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.01.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses in Aquestive Therapeutics to Contact Him Directly to Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.01.2026       Aquestive Therapeutics
US03843E1047

Boston, Massachusetts--(Newsfile Corp. - January 13, 2026) - Block & Leviton is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) for potential securities law violations. Investors who have lost money in their Aquestive Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For mor...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.01.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 09.01.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260109769684/en/ Faruqi & Faruqi is a leading natio...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 09.01.2026       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today provided an update on the regulatory approval of Anaphylm™ and its b...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.10.2025       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended Se...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.10.2025       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the United States Patent and Trademark Office (USPTO) has...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.09.2025       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has info...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.08.2025       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in three upcomin...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.08.2025       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten offering of 21,250,000 shar...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.08.2025       Aquestive Therapeutics
US03843E1047

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a $75 million strategic funding agreement with funds manag...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.07.2025       Aquestive Therapeutics
US03843E1047

WARREN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the promotion of Sherry Korczynski, from Senior Vice Presi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.07.2025       Aquestive Therapeutics
US03843E1047

WARREN, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that Health Canada has granted the Company a meeting to di...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 07.07.2025       Aquestive Therapeutics
US03843E1047

WARREN, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink